Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 2/20 | 0.69 |
| ▸ | GAK | O14976 | 1/20 | 0.69 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.69 |
| ▸ | ULK1 | O75385 | 1/20 | 0.69 |
| ▸ | STK10 | O94804 | 1/20 | 0.69 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.69 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.69 |
| ▸ | LATS1 | O95835 | 1/20 | 0.69 |
| ▸ | PAK4 | O96013 | 1/20 | 0.69 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.69 |
| ▸ | LCK | P06239 | 1/20 | 0.69 |
| ▸ | CDK1 | P06493 | 1/20 | 0.69 |
| ▸ | APRT | P07741 | 1/20 | 0.69 |
| ▸ | RET | P07949 | 1/20 | 0.69 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.69 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.69 |
| ▸ | NQO2 | P16083 | 1/20 | 0.69 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.69 |
| ▸ | FECH | P22830 | 1/20 | 0.69 |
| ▸ | MARK3 | P27448 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5764183 | 0.99 | CDK2 (0.68) | CDK2GAKRIPK2ULK1STK10 | |
| SCHEMBL5766337 | 0.88 | IRAK4 (0.71) | CDK2GAKRIPK2ULK1STK10 | |
| SCHEMBL5763184 | 0.86 | IRAK4 (0.71) | CDK2GAKRIPK2ULK1STK10 | |
| SCHEMBL859537 | 0.85 | IRAK4 (0.72) | CDK2GAKRIPK2ULK1STK10 | |
| SCHEMBL31060494 | 0.85 | IRAK4 (0.72) | CDK2GAKRIPK2ULK1STK10 | |
| SCHEMBL29678517 | 0.85 | IRAK4 (0.72) | CDK2GAKRIPK2ULK1STK10 | |
| SCHEMBL4681654 | 0.85 | FGFR1 (0.57) | CDK2GAKRIPK2ULK1STK10 | |
| SCHEMBL5766748 | 0.85 | CDK2 (0.69) | CDK2GAKRIPK2ULK1STK10 | |
| SCHEMBL5765302 | 0.84 | GAK (0.52) | CDK2GAKRIPK2ULK1STK10 | |
| SCHEMBL3836322 | 0.84 | IRAK4 (0.69) | CDK2GAKRIPK2ULK1STK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1641780-B1 | PROCESSES FOR THE PREPARATION OF 1- [(BENZOIMIDAZOLE-1YL) QUINOLIN-8-YL] PIPERIDIN-4-YLAMINE DERIVATIVES | PFIZER PROD INC (US) | 2008-11-12 | — | — | EP | claimed |
| JP-2007516168-A | — | — | 2007-06-21 | — | — | JP | claimed |
| US-7183414-B2 | Processes for the preparation of benzoimidazole derivatives | PFIZER INC (US) | 2007-02-27 | — | — | US | claimed |
| EP-1641780-A1 | PROCESSES FOR THE PREPARATION OF 1- [(BENZOIMIDAZOLE-1YL) QUINOLIN-8-YL] PIPERIDIN-4-YLAMINE DERIVATIVES | Pfizer Products Incorporated (US) | 2006-04-05 | — | — | EP | claimed |
| EP-1594858-A2 | NOVEL BENZOIMIDAZOLE DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS | Pfizer Products Inc. (US) | 2005-11-16 | — | — | EP | claimed |
| US-20050124599-A1 | Novel benzoimidazole derivatives useful as antiproliferative agents | PFIZER INC. | 2005-06-09 | — | — | US | claimed |
| US-20050020625-A1 | Processes for the preparation of benzoimidazole derivatives | PFIZER INC | 2005-01-27 | — | — | US | claimed |
| WO-2004113322-A1 | PROCESSES FOR THE PREPARATION OF 1-[(BENZOIMIDAZOLE-1YL) QUINOLIN-8-YL] PIPERIDIN-4-YLAMINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2004-12-29 | — | — | WO | claimed |
| WO-2004020431-A2 | NOVEL BENZOIMIDAZOLE DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS | PFIZER PRODUCTS INC. (US) | 2004-03-11 | — | — | WO | claimed |
| EP-1641780-B1 | PROCESSES FOR THE PREPARATION OF 1- [(BENZOIMIDAZOLE-1YL) QUINOLIN-8-YL] PIPERIDIN-4-YLAMINE DERIVATIVES | PFIZER PROD INC (US) | 2008-11-12 | — | — | EP | disclosed |
| US-7183414-B2 | Processes for the preparation of benzoimidazole derivatives | PFIZER INC (US) | 2007-02-27 | — | — | US | disclosed |
| US-7071337-B2 | Benzoimidazole derivatives useful as antiproliferative agents | PFIZER INC (US) | 2006-07-04 | — | — | US | disclosed |
| EP-1641780-A1 | PROCESSES FOR THE PREPARATION OF 1- [(BENZOIMIDAZOLE-1YL) QUINOLIN-8-YL] PIPERIDIN-4-YLAMINE DERIVATIVES | Pfizer Products Incorporated (US) | 2006-04-05 | — | — | EP | disclosed |
| EP-1594858-A2 | NOVEL BENZOIMIDAZOLE DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS | Pfizer Products Inc. (US) | 2005-11-16 | — | — | EP | disclosed |
| US-20050124599-A1 | Novel benzoimidazole derivatives useful as antiproliferative agents | PFIZER INC. | 2005-06-09 | — | — | US | disclosed |
| US-20050020625-A1 | Processes for the preparation of benzoimidazole derivatives | PFIZER INC | 2005-01-27 | — | — | US | disclosed |
| WO-2004113322-A1 | PROCESSES FOR THE PREPARATION OF 1-[(BENZOIMIDAZOLE-1YL) QUINOLIN-8-YL] PIPERIDIN-4-YLAMINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2004-12-29 | — | — | WO | disclosed |
| WO-2004020431-A2 | NOVEL BENZOIMIDAZOLE DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS | PFIZER PRODUCTS INC. (US) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124599-A1 | Novel benzoimidazole derivatives useful as antiproliferative agents | CCNI, CCNT1, CCNA1 | CDK2 19/4885GAK 526/4885RIPK2 3316/4885 |
| US-20050020625-A1 | Processes for the preparation of benzoimidazole derivatives | CCNI, CCNT1, CCNE1 | CDK2 32/4885GAK 654/4885RIPK2 3569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.